New hope for aggressive brain cancer? drug trial targets recurrent glioblastoma
NCT ID NCT06894225
First seen May 01, 2026 · Last updated May 24, 2026 · Updated 4 times
Summary
This study tests a drug called ACT001 in 12 adults whose glioblastoma (a severe brain cancer) has come back after standard treatment. Only patients with a specific genetic marker (STAT3-high) are included. The goal is to see if the drug can shrink or stabilize the tumor for at least 24 weeks, and to measure how long patients live without the cancer growing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT GLIOBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National Neuroscience Institute
Singapore, Singapore
Conditions
Explore the condition pages connected to this study.